Last reviewed · How we verify

Glycopyrronium MDI — Competitive Intelligence Brief

Glycopyrronium MDI (Glycopyrronium MDI) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anticholinergic. Area: Respiratory.

phase 2 Anticholinergic Muscarinic receptors Respiratory Small molecule Live · refreshed every 30 min

Target snapshot

Glycopyrronium MDI (Glycopyrronium MDI) — Pearl Therapeutics, Inc.. Anticholinergic

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Glycopyrronium MDI TARGET Glycopyrronium MDI Pearl Therapeutics, Inc. phase 2 Anticholinergic Muscarinic receptors
SOLIFENACIN SUCCINATE SOLIFENACIN SUCCINATE marketed Muscarinic receptors 2004-01-01
DICYCLOMINE DICYCLOMINE marketed Antispasmodic and anticholinergic (antimuscarinic) agent Muscarinic receptors 1950-01-01
Aceclidin ACECLIDINE marketed aceclidine muscarinic receptors
Tolterodine Tartrate ER Tolterodine Tartrate ER University of California, San Francisco marketed Muscarinic receptor antagonist M2 and M3 muscarinic receptors
Tolterodine 6 Tolterodine 6 KYU-SUNG LEE marketed Muscarinic receptor antagonist M2 and M3 muscarinic receptors
Xanomeline and Trospium Chloride Xanomeline and Trospium Chloride Collaborative Neuroscience Research, LLC marketed Muscarinic M1/M4 receptor agonist with peripheral anticholinergic antagonist Muscarinic acetylcholine receptors M1 and M4 (xanomeline); muscarinic receptors peripherally (trospium chloride antagonism)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Anticholinergic class)

  1. · 4 drugs in this class
  2. Pearl Therapeutics, Inc. · 3 drugs in this class
  3. Shionogi · 2 drugs in this class
  4. Ain Shams University · 1 drug in this class
  5. Astellas Pharma Inc · 1 drug in this class
  6. Boehringer Ingelheim · 1 drug in this class
  7. Covis · 1 drug in this class
  8. Forest Labs Inc · 1 drug in this class
  9. Fougera Pharms · 1 drug in this class
  10. Glaxo Grp England · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Glycopyrronium MDI — Competitive Intelligence Brief. https://druglandscape.com/ci/glycopyrronium-mdi. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: